よむ、つかう、まなぶ。
参考資料14 高齢者がん医療Ｑ＆Ａ総論（厚生労働科学研究「高齢者がん診療指針策定に必要な基盤整備に関する研究」） (79 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_28073.html |
| 出典情報 | がん対策推進協議会（第82回 9／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
cell lung cancer. Support Care Cancer. 2009; 17: 315-320
5)
Matsuda C et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14
(Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer
chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2015; 76: 97-103
6)
Kono T et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2,
multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent
oxaliplatin‑induced neuropathy. Cancer Chemother Pharmacol. 2013; 72: 1283-1290
7)
Hoshino N et al. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy:
a systematic review and meta-analysis. Int J Clin Oncol. 2018; 23: 434-442
8)
Kaku H et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral
neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.
Exp Ther Med. 2012; 3: 60-65
9)
Takegawa Y et al. Can Kampo therapy prolong the life of cancer patients?
J Med Invest.
2008; 55: 99-105
10) Ogawa-Ochiai K et al. Kampo for cancer care: significance as supportive measures. In:
Motoo Y (Ed.) "Traditional Medicine: New Research", New York, Nova Science Publishers;
2012. p1-14
11) Yamakawa J et al. Role of Kampo medicine in integrative cancer therapy. Evid Based
Complement Alternat Med. 2013; 570848
71
5)
Matsuda C et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14
(Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer
chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2015; 76: 97-103
6)
Kono T et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2,
multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent
oxaliplatin‑induced neuropathy. Cancer Chemother Pharmacol. 2013; 72: 1283-1290
7)
Hoshino N et al. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy:
a systematic review and meta-analysis. Int J Clin Oncol. 2018; 23: 434-442
8)
Kaku H et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral
neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.
Exp Ther Med. 2012; 3: 60-65
9)
Takegawa Y et al. Can Kampo therapy prolong the life of cancer patients?
J Med Invest.
2008; 55: 99-105
10) Ogawa-Ochiai K et al. Kampo for cancer care: significance as supportive measures. In:
Motoo Y (Ed.) "Traditional Medicine: New Research", New York, Nova Science Publishers;
2012. p1-14
11) Yamakawa J et al. Role of Kampo medicine in integrative cancer therapy. Evid Based
Complement Alternat Med. 2013; 570848
71